Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 12/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28951 | 1.00 | RAPGEF4 (0.59) | RAPGEF4ACHECA1CA2MMP1 | |
| SCHEMBL28482658 | 0.96 | RAPGEF4 (0.56) | RAPGEF4ACHECA1CA2MMP1 | |
| SCHEMBL10412763 | 0.96 | RAPGEF4 (0.56) | RAPGEF4ACHECA1CA2MMP1 | |
| SCHEMBL5180888 | 0.96 | RAPGEF4 (0.56) | RAPGEF4ACHECA1CA2MMP1 | |
| SCHEMBL6255294 | 0.93 | RAPGEF4 (0.53) | RAPGEF4ACHECA1CA2MMP1 | |
| SCHEMBL4701345 | 0.87 | RAPGEF4 (0.48) | RAPGEF4ACHECA1CA2MMP1 | |
| SCHEMBL10659964 | 0.87 | RAPGEF4 (0.48) | RAPGEF4ACHECA1CA2MMP1 | |
| SCHEMBL28656262 | 0.84 | RAPGEF4 (0.46) | RAPGEF4ACHECA1CA2MMP1 | |
| Butadiene SCHEMBL11268131 | 0.84 | RAPGEF4 (0.46) | RAPGEF4ACHECA1CA2MMP1 | |
| SCHEMBL30448595 | 0.82 | RAPGEF4 (0.43) | RAPGEF4ACHECA1CA2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| EP-2313193-A2 | IMPROVED PROCESS FOR CONVERTING AN OXYGENATED FEED TO HIGH OCTANE GASOLINE | Conocophillps Company (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | GILEAD PHARMASSET LLC | 2007-04-05 | — | — | US | disclosed |
| EP-0000432-B1 | A PROCESS FOR EFFECTING CATALYTIC ISOMERIZATION OF MONOCYCLIC METHYL-SUBSTITUTED AROMATIC HYDROCARBON COMPOUNDS | MOBIL OIL CORPORATION (US) | 1983-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | ENTPD5, DUT, NT5C3B | RAPGEF4 2883/4885ACHE 4224/4885CA1 4663/4885 |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, DUT, NT5C3B | RAPGEF4 2746/4885ACHE 4159/4885CA1 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.